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Abstract
Background: Storage lower urinary tract symptoms (LUTS) including overactive bladder (OAB) and urinary incontinence
(UI) affect millions of people worldwide, significantly impacting quality of life. Plant based medicines have been
documented both empirically and in emerging scientific research to have varying benefits in reducing bladder
symptoms. We assessed the efficacy of Urox®, a proprietary combination of phytomedicine extracts including, Cratevox™
(Crataeva nurvala) stem bark, Equisetem arvense stem and Lindera aggregata root, in reducing symptoms of OAB and UI.
Methods: Efficacy of the herbal combination on a variety of bladder symptoms compared to an identical placebo, were
documented in a randomised, double-blind, placebo controlled trial conducted at two primary care centres. Data were
collected at baseline, 2, 4 and 8 weeks, with the primary outcome being self-reported urinary frequency. Statistical analysis
included mixed effects ordered logistic regression with post hoc Holm’s test to account for repeated measures, and
included an intention-to-treat analysis.
Results: One hundred and fifty participants (59% female, aged; mean ± SD; 63.5 ± 13.1 years) took part in the study. At
week 8, urinary day frequency was significantly lower (OR 0.01; 95%CI 0.01 to 0.02; p < 0.001) in response to treatment
(mean ± SD; 7.69 ± 2.15/day) compared to placebo (10.95 ± 2.47/day). Similarly, episodes of nocturia were significantly
fewer (OR 0.03; 95%CI 0.02 to 0.05) after 8 weeks of treatment (2.16 ± 1.49/night) versus placebo (3.14 ± 1.36/night).
Symptoms of urgency (OR 0.02; 95%CI 0.01 to 0.03), and total incontinence (OR 0.03; 95% CI 0.01 to 0.06) were also lower
(all p< 0.01) in the treatment group. Significant improvements in quality of life were reported after treatment in
comparison to placebo. No significant side effects were observed resulting in withdrawal from treatment.
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Conclusions: The outcome of this study demonstrated both statistical significance and clinical relevance in reducing
symptoms of OAB, urinary frequency and/or urgency and incontinence. The demonstrated viability of the herbal
combination to serve as an effective treatment, with minimal side-effects, warrants further longer term research and
consideration by clinicians.
Trial registration: NCT02396160 (registered on 17 March 2015 - before any statistical analyses commenced).
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Background
Lower urinary tract symptoms (LUTS) are subjective and
divided into subgroups with the three major groups as stor-
age, voiding and post micturition symptoms. Storage LUTS
include increased day frequency, nocturia, urgency, and
urinary incontinence. Urinary incontinence can be subdi-
vided further into stress, urgency, a mixture of both stress
and urgency, and the less common, enuresis, continuous
and other types such as situational incontinence [1]. Void-
ing LUTS include slow stream, splitting/spraying, intermit-
tency, straining and terminal dribble. Post micturition
symptoms include feeling of incomplete emptying and post
micturition dribble. Storage LUTS include Overactive blad-
der (OAB) and urinary incontinence (UI) and are embar-
rassing and distressing conditions suffered by millions.
These conditions can negatively impact the physical and
emotional status and quality of life in those affected [2–4].
OAB is characterized by symptoms of urinary urgency, with
or without leakage (urgency incontinence), day frequency,
and nocturia. Urinary incontinence may also be described
as occurring due to stress (stress incontinence), where pres-
sure is placed on the pelvic floor muscles such as in cases
of sneezing or heavy lifting, where the urinary loss occurs
without warning or the sense of urgency beforehand (ur-
gency incontinence) or a mixture of both [2].
Current estimates suggest 4.8 million Australians suffer
with urinary incontinence, while 15% of the population ex-
perience OAB [5]. It is estimated that 33 million Americans
suffer from OAB with 12.2 million of these adults also hav-
ing concomitant urgency incontinence [2, 6]. A 2002 study
of 5 other western countries (i.e., Canada, Germany, Italy,
Sweden and the United Kingdom) demonstrated that on
average, OAB prevalence was around 11.8% and UI 9.4%
[7]. These conditions pose an enormous health cost burden.
In 2000, these costs totalled US$19.5 billion for urinary in-
continence alone in the United States [8].
Contrary to popular understanding, men and women
have a similar prevalence of overactive bladder, with ur-
gency incontinence occurring more often in males [2, 6, 9].
Less than 50% of men with lower urinary tract symptoms
(LUTS) have urodynamically proven bladder outlet ob-
struction that may be attributed to BPH or other obstruct-
ive causes [10, 11]. Men with BPH may be prescribed
phosphodiesterase type 5 (PDE5) inhibitors such as
tadalafil, although the more commonly prescribed medica-
tions for male LUTS attributed to BPH are alpha-
adrenergic agents to relax the urethral and prostate smooth
muscle and/or 5-alpha reductase inhibitors to reduce an-
drogen production and prostate growth. Side effects from
these two classes of medications include hypotension, erect-
ile dysfunction and/or reduced libido. For the 50% of men
with LUTS due to storage problems, predominantly OAB,
their response to these medications is limited [1].
Combined, stress and urgency UI affects approximately
25% of reproductive age women, 50% of post-menopausal
women, and 50%–75% of women in nursing homes [3,
12]. Despite this, UI remains under-diagnosed and under-
reported [3] with many women perceiving UI as a ‘normal’
part of being female [13]. Factors contributing to urinary
incontinence include, child birth (40% of women suffer
some form of leaking urine after bearing children) [14],
constipation and other bowel symptoms, a high body mass
index, as well as, a history of hysterectomy, prostatectomy
or prolapse repair [15].
Current popular treatment options for UI and OAB in-
clude pelvic muscle rehabilitation, behavioural techniques
such as bladder retraining, and drug therapies [9]. Common
drugs used in the treatment of UI and OAB are oxybutynin,
tolterodine and fesoterodine, anticholinergic muscarinic re-
ceptor antagonists, intended to reduce symptoms of OAB
and UI with variable outcomes [16, 17]. However, some
anticholinergic drugs can effect tissues other than the blad-
der resulting in poorly tolerated side effects including dry
mouth, dry eyes, constipation and memory loss [18], and in-
creased discontinuation of treatment within a two to twelve
month timeframe [19]. Other reported side effects include
blurred vision, nausea and drowsiness [20]. Recent research
has documented anticholinergic and antimuscarinic drugs,
including high dose oxybutynin, may produce irreversible
cognitive impairment and an increased risk for dementia,
particularly with chronic use [21]. This has led to recent
recommendations to minimise anticholinergic use, in gen-
eral, over time [22, 23]. Despite recent approval of add-
itional pharmaceutical medications which are more specific
to bladder tissue for the treatment of OAB and UI, such as
darifenacin, solifenacin and trospium, these have not been
reported to date to result in cognitive impairment, however,
unwanted anticholinergic effects in tissues other than the
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bladder continue to be reported. Even administration of
slow release or transdermal delivery systems have not elimi-
nated unwanted systemic anticholinergic side effects [24].
Phytomedicine therapies have been traditionally used
in the treatment of symptoms of OAB and UI [25–28].
Both previous and emerging clinical research into the
use of phytomedicines demonstrates an increasing bene-
fit from these approaches, often without the side effects
that are associated with prescription medications. How-
ever, few have been subjected to controlled clinical trials
to evaluate their safety and efficacy. The specific phyto-
medicines used in the herbal combination, Crataeva,
Equisetum and Lindera, have well established traditional
uses [25–27] and as such considered safe for human
consumption [29].
In Ayurvedic Medicine, Crataeva nurvala is the herb
of choice for urinary disorders [30]. A review of research
shows Crataeva produced hypertonic curves in dog
cystometric studies and increased bladder tone and blad-
der capacity in humans in cases of hypotonic bladder
due to prostatic hypertrophy [28]. Crataeva demon-
strated beneficial effects on neurogenic bladder and sig-
nificantly decreased residual urine volume, normalising
the tone of the urinary bladder. Crataeva has also been
shown to be effective in the treatment of urinary calculi
and infection [28, 31–35].
Western herbal medicine traditionally recommends
Equisetum arvense as a genito-urinary astringent for
urinary incontinence and enuresis in children [27]. The
silica content of Equisetum likely contributes to the
astringent effects. Equisetum has also been shown to
have anti-inflammatory, anti-bacterial and anti-
lithogenic effects [27, 36–38]. A pilot trial with Equi-
setum and Crataeva showed this combination reduced
urinary frequency, urgency incontinence and stress in-
continence episodes, which was attributed to improved
tone of the urinary bladder and pelvic floor [39]. A ran-
domised controlled trial with Crataeva and Equisetum
alone, showed statistically significant reductions in day
frequency and urinary incontinence and improved qual-
ity of life within two months of treatment, however,
drop-out was high (23%) [29] in addition, Human cyto-
chrome P450 (CYP1A2 and CYP3A4) in vitro testing on
immortalised human hepatocytes (Fa2N-4 cells) showed
that the combination of Crataeva and Equisetum caused
no interference with these liver enzymes involved in
drug metabolism, indicating that the combination of the
two herbs was safe when consumed with other medica-
tions [40]. Lindera aggregata, another herb, is documented
in texts of traditional Chinese medicine for frequent
urination and urinary incontinence due to cold from a
deficient bladder [25]. Lindera promotes the movement
of chi or energy and blood and disperse cold, especially
in the lower abdomen [25].
Urox (herbal combination used in the current study) con-
tains Crataeva, Equisetum and Lindera. Urox is listed as
safe for human consumption with the Therapeutic Goods
Administration (TGA) in Australia since 2011 and is being
sold in the USA and Australia since 2012. Company docu-
mentation (personal communication with Seipel Group) in-
dicate less than 0.07% of adverse event (predominantly
worsening bladder symptoms, digestive complaints and al-
lergy to the formula) between 2012 and 2017 with no re-
port of any interference with drug medications. It is
speculated that the efficacy of Urox to be due to an anti-
spasmodic effect as a result of an improvement in the tone
of the bladder’s muscles [28, 29]. Urox was intended as an
improved formulation with a faster action, therefore results
from the current study are required within the two-month
timeframe to assess its efficacy in comparison to the previ-
ous formulations [29, 39].
As pharmaceutical treatment options for UI and OAB
have limited effectiveness and are associated with a
range of adverse side effects, and given the paucity of
competent and reliable studies of phytomedicine treat-
ments to substantiate efficacy and/or safety, we assessed
the effectiveness of Urox, the herbal combination of
Crataeva, Equisetum and Lindera towards resolving UI
and/or symptoms of OAB, such as urinary frequency
and urgency within a two-month time frame.
Methods
This study was conducted over an 8-week period in a
phase-2, parallel double-blinded, randomised controlled
design. Adults over the age of 18 years with symptoms
of UI and/or OAB were recruited via a variety of adver-
tising media including newspapers advertisements and
notices posted at community centres. Self-identified par-
ticipants were initially screened for suitability via tele-
phone by research clinicians, based on definitions
outlined by the Standardization Committee of the Inter-
national Continence Society.
Ethics, consent and permissions
The study was approved by the Ethics Committee of En-
deavour College of Natural Health (Queensland, Australia;
approval number HREC #12/030). All participants provided
written informed consent.
Inclusion criteria, based on an adult only population, in-
cluded those who experienced in the most recent six
months, symptoms such as: urinary day frequency (≥10/
day), nocturia (≥2/night), urgency (≥2/day), and incontin-
ence (≥1/day). To be eligible, participants needed to have
a minimum of 2 of these symptoms. Urodynamics were
not performed, patients were recruited solely on the basis
of their symptoms, as the former is invasive and provides
only a brief snapshot of bladder function under artificial
conditions [41]. Participants with comorbidities such as
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controlled hypertension, osteoarthritis, controlled dia-
betes, anxiety, chronic obstructive pulmonary disease, etc.,
were included in the study. These diseases/disorders were
not expected to confound the results.
Exclusion criteria included: recent (≤1 year) relevant sur-
geries such as hysterectomy, prolapse repair, prostate sur-
gery, childbirth/currently pregnancy; current use of any
natural therapies for bladder symptoms or prescribed medi-
cation for UI or OAB; unregulated doses of diuretics; under-
going treatment for mental health issues or psychiatric
disturbances; other concomitant health conditions, includ-
ing uncontrolled diabetes mellitus, heart disease, pancreatic,
hepatic or renal disease, neurologic disease, recurrent urin-
ary tract infections, benign prostatic hypertrophy, continual
leakage, menstrual cycle-related incontinence, and chronic
inflammatory conditions.
Randomisation
Participants meeting the above criteria, provided written in-
formed consent and were randomised via the block of four
method (using Microsoft Excel® command “Rand”) by a
third party, into either treatment or placebo as indicated by
either blue or yellow stickers on identical product bottles
and allocated patient files. Both participants and researchers
remained blinded to treatment allocation until after com-
pletion of statistical analyses, to ensure no risk of bias for
the entire duration of the study and into completion. Treat-
ment allocation was provided by a 3rd party external to the
researchers and clinicians and was not disclosed until after
statistical analysis, also minimising the chance of bias.
Interventions
Each capsule contained 420 mg of a proprietary blend of
Urox® (Seipel Group, Brisbane, Australia) containing Crate-
vox™ (Crataeva nurvala L.; Capparidaceae; Varuna) stem
bark extract standardised for 1.5% lupeol; non-standardised
Equisetum arvense L. (Equisetaceae; horsetail) stem extract;
and, non-standardised Lindera aggregata Sims. (Lauraceae;
Japanese evergreen spicebush) root extract. The placebo
contained a colour-matched vegetarian capsule containing
colour-matched cellulose. Identity of each plant was con-
firmed prior to manufacture of the finished capsule via high
performance thin layer chromatography (HPLC) for Cra-
taeva and Equisetum (Southern Cross University, Lismore,
New South Wales, Australia) and Lindera (Alkemist Labs,
Costa Mesa, California, USA). Crataeva and Equisetum
were wild-crafted and grown without the use of pesticides.
Lindera was cultivated and was tested for pesticide residue
by gas chromatography mass spectroscopy (GC-MS).
Capsules were manufactured in a Therapeutic Goods
Administration licensed facility according to the PIC/S
Guide to Good Manufacturing Practice for Medicinal
Products, PE 009–9-15 January 2009. Capsules underwent
microbiological and heavy metal testing to ensure they
complied with product specifications. The dosage was two
capsules per day taken once daily with food. The dosage
regimen was determined based on earlier research with
Crataeva and Equisetum alone [29], pharmacopeia and
traditional herbal textbook dosage recommendations, and
earlier, unpublished research with the Crataeva, Equi-
setum and Lindera blend [25–28].
Initial consultations were held at two Brisbane outpatient
centres. Follow-up interviews were conducted via tele-
phone. Participants were telephoned approximately one
week before the scheduled interview and were intermit-
tently called during the week thereafter if they were unable
to be reached to schedule an alternative interview time.
The clinicians conducting interviews were herbalists with
additional qualifications in naturopathic medicine, acu-
puncture and/or traditional Chinese medicine. In Australia,
herbalists are regulated either by the National Herbal Asso-
ciation of Australia (NHAA) or, if the herbalist has multiple
qualifications which is often the case, they are regulated by
other professional association bodies (e.g., the Australian
Acupuncture and Chinese Medicine Association, the Aus-
tralian Naturopathic Practitioners Association, etc.).
The week prior to initial consultation participants
were requested to complete a micturition diary and rele-
vant health related quality of life surveys. The attending
clinician completed a clinical data sheet, containing a
range of questions including demographics, exercise,
health history and personal habits. Any incomplete qual-
ity of life surveys at outset were completed during the
initial interview. Micturition diaries were collected by
post at 2, 4 and 8 week intervals, along with the comple-
tion of quality of life surveys and follow up clinical data
sheet via telephone. Participants were asked to keep the
micturition diary for 3 days prior to each consultation
and were provided reply paid envelopes to return the
surveys and any unused capsules to assess compliance.
The primary outcome measure was urinary frequency
defined as the number of voluntary diurnal and/ or noc-
turnal micturitions, self-reported via a validated urinary
diary method per Wyman [42]. These diaries are designed
to assist with the collation of urinary symptoms for 3 con-
secutive days, where participants indicate the number of
times each symptom occurs. Relevant symptoms include
urinary frequency, urgency, urgency incontinence or stress
incontinence. Long-term diaries decrease patient compli-
ance while a 3-day diary is reported as reliable to that of a
7-day record [43]. Secondary outcome measures included
number of urinary urgency episodes/day, and number of
incontinence episodes/day, using the same diary technique
as for the primary measure.
Health-related quality of life (HR-QOL) was measured
using condition specific, previously validated standar-
dised instruments outlined elsewhere [44–47]. These
surveys included the short versions of the Overactive
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Bladder Questionnaire (OAB-SF; maximum score for
each question = 6), which was administered if symptoms
of urgency and/or frequency existed, while the Urinary
Distress Inventory (UDI; maximum score for each ques-
tion = 4) and Incontinence Impact Questionnaire (IIQ;
maximum score for each question = 4) were utilised in
cases of urinary incontinence.
Information regarding number and type of incontin-
ence pad/diaper usage per week was collected from all
participants at each time point. At the completion of the
trial participants were asked if they found any benefit
from the treatment and whether they would be willing
to continue treatment with this medication.
Analysed outcome data was collected via patients’ self-
evaluation and returned by patients via mail in order to
minimise clinicians and researchers chance to elicit any
hypothetical bias and influence outcomes. Once received,
diary responses were filed until data entry and subsequent
analyses. Participants were not patients of the interviewing
clinicians and their postal outcome results were not consid-
ered or evaluated for the duration of the trial. These follow
up interviews consisted of quality of life questions as well as
questions to ascertain any changes in participants’ lifestyle,
which might otherwise confound results such as changes in
exercise, water intake, diet or extraneous stress, or newly
presenting medical conditions and medication changes.
Sample size calculation and statistical analysis
For the primary outcome (day frequency), based on earlier
research using a Crataeva and Equisetum combination
[29], it was calculated that 45 participants in each of the 2
groups were required to detect a difference of 1.6 (±2.7)
urinary frequency episodes per day between treatment
and placebo groups, with a two-tailed alpha of 0.05 and a
power of 80%. For total incontinence, 53 participants were
required to detect a difference of 1.2 (±2.2) incidents/day,
while for urgency 54 participants were required in each
group to detect a difference of 2 (±3.7) incidents/day. To
account for potential drop-outs and variations in present-
ing symptoms, a total of 150 participants (75/group) were
recruited. Participants were enrolled if they presented with
at least two of the four assessable symptoms: day fre-
quency, urgency, nocturia, and/or incontinence.
One person was responsible for data transfer from
paper copies to the electronic database. Although
double data entry was not performed, 10% of the data
was randomly checked until no mistakes were found.
Less than 1% changes were made to the data set follow-
ing this procedure. All data except for day frequency
was non-normally distributed. Residuals (difference be-
tween predicted and actual observed value) of linear re-
gression model for all variables did not meet the
assumptions of linear regression. Hence, all compari-
sons for the two treatments (as change from baseline)
were made using mixed effects ordered logistic regres-
sion adjusted for repeated measures (Stata, v. 13.1, Sta-
taCorp, TX, USA) as this model does not require the
assumptions of linear regression to be true. Holm esti-
mation test was used to adjust p-values for repeated
measures. Analyses included only participants who were
symptomatic at baseline for each parameter investi-
gated. Data (day frequency, nocturia, urgency and in-
continence) were evaluated by per-protocol and
intention-to-treat analysis, with the last result brought
forward for participants who dropped out or were lost
to follow-up. Backward stepwise regression (p < 0.22 for
covariate inclusion) indicated small effect of age, gender,
water intake and diuretic use on the outcome model.
However, result for adjusted and non-adjusted data
were similar, hence unadjusted analyses is presented.
Responses to questionnaires were grouped for ease of
reporting. The OAB-SF was analysed if the participant
experienced urgency at baseline. The change from base-
line is reported for the total of all OAB-SF questions, as
well as sub-grouped according to classifications of symp-
tom bother (questions 1–6; maximum score 36); diffi-
culty coping (questions 7, 10, 11, 14, 19; maximum score
30); concern/worry (questions 8, 12, 16; maximum score
18); interference in sleep (questions 9, 13, 17; maximum
score 18) and affects social interaction (questions 15, 18;
maximum score 12). The IIQ questions 1–7 (maximum
score 28) are reported as a total as are the responses to
UDI questions 8–13 (maximum score 24).
Results
Participants were recruited and data collected from April
2013 until November 2014. One hundred and fifty partici-
pants consented to take part in the study (Fig. 1), and 142
(73 (97%) placebo, 69 (92%) treatment) completed the study.
Drop-outs included two participants from the placebo group
and six from the treatment group. None of these with-
drawals were due to the study interventions but were for
personal reasons. None of the adverse events reported were
severe enough to cause withdrawal. Baseline demographic
and symptom characteristics of placebo and treatment
groups were similar between the two groups (Table 1).
Significant differences were observed at 8-weeks over
all variables, with symptoms reducing to within normal
range occurring in greater frequency in the treatment
group (Table 2). Resolution of symptoms was indicated
at ≤8/day for day frequency, ≤ 1/night for nocturia and 0
for both urgency and total incontinence (Fig. 2), as out-
lined by the National Association for Continence [2].
Baseline results for all HR-QOL variables were similar
between the two intervention groups (all p > 0.18). Sig-
nificant improvements (all p < 0.001) were noted in par-
ticipants’ perceptions after 8-weeks of the treatment
compared to placebo (Fig. 3).
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Differences in OAB-SF parameters (60 in placebo and 58
in treatment group) between the herbal combination and
placebo (analysed as change from baseline) for those with
symptoms of urgency at baseline included: bothersome
(mean diff − 11.53; 95% CI -13.15 to − 9.90); difficulty in
coping (− 7.57; − 8.71 to − 6.43), concern/worry (− 4.41; −
5.30 to − 3.52), difficulty sleeping (− 6.51; − 7.58 to − 5.44)
and social interaction (− 1.14; − 1.59 to − 0.68) were all sig-
nificantly lower (p < 0.01 based on logistic regression ana-
lyses) at the end of treatment compared to placebo. Total
OAB-SF was significantly lower (− 30.83; − 34.75 to − 26.93;
p < 0.001) after Urox than with placebo. Total scores for
IIQ for those with incontinence at baseline were also sig-
nificantly lower (− 7.56; − 9.30 to − 5.82) after the herbal
combination than placebo. UDI responses for all partici-
pants were also significantly lower (− 5.45; − 6.65 to − 4.25)
after 8-weeks of Urox, compared to placebo.
To assess whether the differences observed between the
placebo and the Urox at week-8 were clinically relevant,
we calculated the Cohen’s d effect size for each variable
using week-8 values. Results showed a large (Cohen’s d ≥
0.6) effect of the herbal combination on all urinary
Fig. 1 Participant flow through the study
Table 1 Demographic and symptom characteristics of study
population at the start of the trial
Variable Placebo Treatment
Participants 75 75
Sex (Female %) 48 (64%) 40 (53%)
Age (years; mean ± SD) 62.48 ± 13.70 64.55 ± 12.42
Weight (kg; mean ± SD) 79.23 ± 22.47 78.53 ± 18.94
Day frequency≥ 10 (n,%) 57 (76%) 50 (67%)
Nocturia ≥2 (n,%) 60 (80%) 70 (93%)
Urgency ≥2 (n,%) 62 (83%) 63 (84%)
Urgency incontinence≥1 (n,%) 33 (44%) 32 (43%)
Stress incontinence ≥1 (n,%) 9 (12%) 10 (13%)
Any incontinence ≥1 (n,%) 42 (56%) 35 (47%)
Only two symptoms (n,%) 25 (30%) 26 (35%)
Only three symptoms (n,%) 29 (39%) 30 (30%)
All four symptoms (n,%) 21 (28%) 19 (25%)
Symptoms include urinary day frequency (≥10/day), nocturia (≥2/night),
urgency (≥2/day), and incontinence (≥1/day) for ≥6 months prior to enrolling
in the study; any incontinence includes urgency, stress and other incontinence
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variables expect for urgency incontinence where the effect
was moderate (Cohen’s d 0.55). Similarly, for HR-QOL
data, we observed Cohen’s d value of above 0.6.
Thirteen cases of transient adverse events were re-
ported, eight from the placebo arm and five from the
treatment group (Table 3).
Comparison of number of pads used and the type of
pad used showed significant differences (both p < 0.001)
at the end of the study when compared between the two
interventions. Approximately 40% of the participants in
both groups (29/72 placebo; 26/69 Urox) reported using
pad/diapers at the start of the study. Considering the use
of 7 or less pads per week (≤1/day) as an indication of
pad use as a precautionary measure, 20 out of 72 and 16
out of 69 participants reported using more than one
pad/diaper a day (i.e. > 7/week) at the start of the study
(week-0), in placebo and treatment groups respectively.
Nineteen participants in the placebo group continued to
use more than one pad/diaper a day at the end of the
study, compared to only four in the Urox group. The
number of individuals using moderate/heavy pads chan-
ged from 20 at baseline to 19 at the end of the study
period in the placebo group, whereas, only six partici-
pants reported using moderate/heavy pads at week-8 in
the Urox group, a reduction from 18 at baseline. Simi-
larly, significantly higher proportion (p < 0.001) of
Table 2 Over active bladder and urinary incontinence symptoms frequency as recorded from micturition diaries
Variable Placebo (mean ± SD) UROX (mean ± SD) OR (95% CI) Placebo vs treatment
Day frequency (n/day)
Week 0 11.57 ± 1.79 11.53 ± 1.54 0.95 (0.33 to 2.73)
Week 2 10.80 ± 2.44 8.94 ± 2.28 0.07 (0.04 to 0.13)*
Week 4 10.60 ± 2.42 8.42 ± 2.46 0.04 (0.02 to 0.08)*
Week 8 10.95 ± 2.47 7.69 ± 2.15 0.01 (0.01 to 0.02)*
Nocturia (n/day)
Week 0 3.39 ± 1.52 4.02 ± 1.62 3.59 (1.39 to 9.21)*
Week 2 2.94 ± 1.37 3.18 ± 1.72 0.40 (0.24 to 0.69)*
Week 4 2.92 ± 1.30 2.70 ± 1.52 0.14 (0.08 to 0.24)*
Week 8 3.14 ± 1.36 2.16 ± 1.49 0.03 (0.02 to 0.05)*
Urgency (n/day)
Week 0 4.34 ± 2.89 3.80 ± 1.82 0.67 (0.23 to 1.94)
Week 2 3.65 ± 2.62 2.32 ± 2.09 0.16 (0.09 to 0.27)*
Week 4 3.52 ± 2.68 1.88 ± 2.25 0.08 (0.04 to 0.13)*
Week 8 3.93 ± 2.87 1.49 ± 2.31 0.02 (0.01 to 0.03)*
Urgency Incontinence (n/day)
Week 0 2.71 ± 2.68 2.79 ± 1.50 1.70 (0.53 to 5.40)
Week 2 2.32 ± 1.54 1.85 ± 1.78 0.19 (0.09 to 0.40)*
Week 4 1.82 ± 1.33 1.53 ± 2.41 0.19 (0.09 to 0.40)*
Week 8 2.44 ± 2.38 1.24 ± 2.49 0.04 (0.02 to 0.09)*
Stress Incontinence (n/day)
Week 0 2.19 ± 1.50 2.13 ± 1.14 0.97 (0.11 to 8.65)
Week 2 1.70 ± 1.49 1.27 ± 1.29 0.30 (0.07 to 1.29)
Week 4 1.85 ± 1.29 0.77 ± 0.94 0.06 (0.01 to 0.25)*
Week 8 2.04 ± 1.51 0.73 ± 0.87 0.03 (0.01 to 0.15)*
Total Incontinence (n/day)
Week 0 2.95 ± 2.65 3.31 ± 2.12 1.97 (0.65 to 5.98)
Week 2 2.56 ± 1.62 2.20 ± 2.09 0.23 (0.11 to 0.45)*
Week 4 2.13 ± 1.42 1.74 ± 2.68 0.14 (0.07 to 0.27)*
Week 8 2.70 ± 2.25 1.38 ± 2.73 0.03 (0.01 to 0.06)*
OR (95% CI): odds ratio and 95% confidence interval for difference between the two treatments (includes participants who did not complete the study);
Comparison made as change from baseline between the two conditions. Holm estimation test was used to adjust p-values for repeated measures
*Significantly different between the two treatments at the specific time; Number of participants assessed for each symptom were according to if their baseline
measures matched the inclusion criteria (see Table 2 for the exact number of participants)
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participants in the Urox group (84%; 58/69) reported
they had benefited from the treatment compared to the
placebo group (18%; 13/72). Furthermore, 77% (53/69)
in the treatment group compared to 29% (21/72) in the
placebo group indicated their willingness to continue
with “this medication” (p < 0.001).
Discussion
This study demonstrated significant efficacy and toler-
ability of the phytomedicine formula, Urox, in the
treatment of UI and symptoms of OAB. A strength of
this study is the lack of side effects typically associ-
ated with anticholinergic/antimuscarinic medications
Fig. 2 Frequency of urinary symptoms averaged over three consecutive days (median, 25 and 75 percentile)
Fig. 3 HR-QOL scores at week-8 on placebo and the Urox treatment. *Significantly different from placebo when compared as change
from baseline
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over the same 8-week period and the significant im-
provement in quality of life.
Our results show that 6 out of 57 (11%) symptomatic
participants from the placebo group reported
normalization of their bladder symptoms for day fre-
quency after week-8 of the trial, compared with 30 out
of 50 (60%) symptomatic participants in the treatment
group. Similarly, for nocturia, 17 of 70 symptomatic par-
ticipants (24%) in the treatment group became symptom
free at the end of the trial compared to only 1 of 60 par-
ticipants (less than 2%) in the placebo group. Five of
these 17 participants in the treatment group reported re-
versal of the condition at week-2 and remained asymp-
tomatic to the end of the trial. Twenty percent (13/63)
of participants (with baseline urgency of 2 or more epi-
sodes a day) in the treatment group reported urgency of
zero at the end of the trial period, compared to only
three participants (out of 62) in the placebo group.
Twenty-three percent (8/35) of the participants in the
Urox group reported to be incontinence free at the end
of 8 weeks compared to 7 % in the placebo group (3/42).
Urox produced more extensive benefits for symptoms
of OAB and UI than has been shown with earlier herbal
research, and within a shorter timeframe. A 12-week
randomised trial with women using a pumpkin seed ex-
tract (Cucurbita pepo.) and a proprietary soy germ ex-
tract (Glycine max) combination showed no significance
in reducing incontinence [48]. Whilst frequency, urgency
and nocturia improved, the magnitude of effect was con-
sistently less and time frame for results, longer than with
Urox. An 8-week randomized trial with men using the
herb, Angelica archangelica was assessed for its effects
on nocturnal bladder symptoms and showed no signifi-
cant effect in overall nocturia [49]. Research with whole
cranberry (Vaccinium macrocarpon) fruit powder
showed reductions in urinary urgency, frequency and
nocturia, but again took longer (three to six months)
than demonstrated in this study of Urox [50].
A systematic literature review of pharmaceutical drugs
for urgency and urinary incontinence between 1966 and
2011, concluded that overall the drugs selected for
review produce small benefits, with up to 13% of partici-
pants achieving continence, while approximately 6% of
participants discontinued treatment due to severity of
adverse effects. Also, evidence of improved quality of life
was limited [24]. In contrast, the current study using
Urox, compared to placebo, was well tolerated and sig-
nificantly improved quality of life for study participants.
Halving nocturia within two months of treatment re-
duces the additional debility of interrupted sleep in these
patients, and is considered highly clinically relevant. Re-
ductions in day urinary frequency, urgency and incontin-
ence are also very clinically relevant particularly to
patients whose lives can be continuously interrupted on
a daily basis by needing to use toilet facilities within a
close proximity of their whereabouts. Considering the
demonstrated benefits, lack of serious adverse events,
along with a high rate of patient compliance and partici-
pant satisfaction, the utility of Urox by clinicians seems
worthy of consideration.
As this is a phase-2 clinical trial of 8 weeks duration
without an active comparator, and given the results re-
ported, a longer phase-3 trial is warranted.
Conclusion
The outcome of this randomised controlled trial demon-
strates both statistical significance and clinical relevance
in reducing urinary frequency, OAB and UI symptoms,
over 8 weeks, without side effects commonly seen with
anticholinergic and antimuscarinic medications.
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